Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA

Carcinogenesis

Volumn 33, Issue 9, 2012, Pages 1782-1790

  Gulhati, Pat ^a,c,e   Zaytseva, Yekaterina Y ^a,c   Valentino, Joseph D ^a,c   Stevens, Payton D ^b,c   Kim, Ji Tae ^a,c   Sasazuki, Takehiko ^d   Shirasawa, Senji ^d   Lee, Eun Y ^b,c   Weiss, Heidi L ^c   Dong, Jianli ^e,f   Gao, Tianyan ^b,c   Mark Evers, B ^a,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^e UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^f University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; RAS PROTEIN; S6 KINASE; SORAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; CLINICAL ARTICLE; COLON CARCINOGENESIS; COLONY FORMATION; COLORECTAL CANCER; CONTROLLED STUDY; DISTANT METASTASIS; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TOLERABILITY; ENZYME ACTIVATION; FEEDBACK SYSTEM; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; LIVER METASTASIS; MALE; MONOTHERAPY; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE K RAS; ONCOGENE PIK3CA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZENESULFONATES; CELL CYCLE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG SYNERGISM; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS; PYRIDINES; RAS PROTEINS; SIROLIMUS;

EID: 84865540541     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs203     Document Type: Article

References (30)

1. Philp, A.J. et al. (2001) The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res., 61, 7426-7429.
2. Roy, H.K. et al. (2002) AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis, 23, 201-205.
3. Guertin, D.A. et al. (2007) Defining the role of mTOR in cancer. Cancer Cell, 12, 9-22.
4. Simi, L. et al. (2008) High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am. J. Clin. Pathol., 130, 247-253.
5. Liu, Z. et al. (2008) Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J. Clin. Endocrinol. Metab., 93, 3106-3116.
6. Tsao, H. et al. (2004) Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol., 122, 337-341.
7. Gingras, A.C. et al. (1999) eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu. Rev. Biochem., 68, 913-963.
8. Sarbassov, D.D. et al. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 307, 1098-1101.
9. Gulhati, P. et al. (2009) Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin. Cancer Res., 15, 7207-7216.
10. Guertin, D.A. et al. (2009) The pharmacology of mTOR inhibition. Sci. Signal., 2, pe24.
11. O'Reilly, K.E. et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res., 66, 1500-1508.
12. Carracedo, A. et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest., 118, 3065-3074.
13. Wilhelm, S.M. et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res., 64, 7099-7109.
14. Wilhelm, S.M. et al. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther., 7, 3129-3140.
15. Dal Lago, L. et al. (2008) Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist, 13, 845-858.
16. Takimoto, C.H. et al. (2008) Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother. Pharmacol., 61, 535-548.
17. Rychahou, P.G. et al. (2008) Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc. Natl. Acad. Sci. U.S.A., 105, 20315-20320.
18. Allred, D.C. et al. (1993) Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst., 85, 200-206.
19. Gulhati, P. et al. (2011) mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res., 71, 3246-3256.
20. Chou, T.C. (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res., 70, 440-446.
21. Samuels, Y. et al. (2004) Oncogenic mutations of PIK3CA in human cancers. Cell Cycle, 3, 1221-1224.
22. Shirasawa, S. et al. (1993) Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science, 260, 85-88.
23. Wilhelm, S. et al. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov., 5, 835-844.
24. Heidorn, S.J. et al. (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell, 140, 209-221.
25. Hatzivassiliou, G. et al. (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature, 464, 431-435.
26. Gangadhar, T.C. et al. (2011) Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin. Cancer Res., 17, 1956-1963.
27. Harzstark, A.L. et al. (2011) A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer, 117, 4194-4200.
28. Lasithiotakis, K.G. et al. (2008) Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J. Invest. Dermatol., 128, 2013-2023.
29. Newell, P. et al. (2009) Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J. Hepatol., 51, 725-733.
30. Wang, Z. et al. (2008) Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin. Cancer Res., 14, 5124-5130.